The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
Secretary of Education Betsy DeVos and her family have seen their investments skyrocket since President Donald Trump started enacting pro-business policies. Meanwhile, DeVos...Politicsread more
The construction industry is heavily dependent on Hispanic and Latino workers, a workforce that diminished during the last housing crisis and has not come close to full...Real Estateread more
A group of gold miners stocks, "BAANG," are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
T-Mobile is choosing to move ahead with a merger with Sprint even though it will prop up Dish Network as a new, possibly disruptive fourth U.S. wireless competitor.Technologyread more
Danger is lurking in the stock market: An abrupt sell-off could be around the corner if the Federal Reserve doesn't deliver the rate cut the market expects next week, the firm...Marketsread more
Shares of Beyond Meat jumped 12% Monday afternoon, nearing its all-time high, on investor optimism ahead of its earnings.Food & Beverageread more
Carl Icahn thinks Occidental Petroleum's CEO got played by the Oracle of Omaha himself in the company's effort to buy Anadarko Petroleum.Investingread more
The U.S. Food and Drug Administration has approved the first generic copies of a popular, pricey pill for nerve pain. The agency on Monday said it approved nine generic...Biotech and Pharmaceuticalsread more
Starbucks is licensing its mobile and loyalty program technology in a deal that will give global franchisees the chance to offer the Starbucks mobile app to customers.Restaurantsread more
One of the greatest fears among patients is that a serious condition such as cancer is not picked up until it's too late.
If life-threatening diseases could be tested simply, quickly and cheaply - without invasive procedures and weeks of waiting - the benefits for healthcare providers would be substantial. Plus patients would welcome the increased peace of mind an early diagnosis would bring.
The financial impact of missing an early diagnosis is also significant. Finding cancer early in the U.K. could save the country's National Health Service around £210 million ($336 million) a year in treatment costs, according to research published by Incisive Heath and Cancer Research UK in September.
One company aiming to solve this issue is Miroculus, a start-up which has created technology it says can detect multiple of cancers with a standard blood test that can be used in a GP's surgery – or even someone's home.
"It will change the perception of what cancer means. Today it means very bad news, but if we start detecting cancer early, there will be a better chance of survival and less suffering for both patients and families," Miroculus co-founder and CTO Jorge Soto told CNBC at the Web Summit tech conference in Dublin.
Miroculus' platform works by detecting microRNAs - a type of molecule which can be used to identify illnesses such as cancer, diabetes and even Alzheimer's - from a blood sample using technology and biochemistry usually reserved for high-tech laboratories.
"At the moment this requires very specialised machines the size of my kitchen. They're very expensive and require highly-trained technicians to operate and to analyse the data," Soto added.
Miroculus' platform is designed to be portable, connect to a smartphone and be used outside of the hospital. The company insists the technology – which is undergoing clinical tests in hospitals at the moment - could be ready within five years. Emerging markets – with a severe lack of diagnosis labs – are a key target market for Miroculus.
'Different to a pregnancy test'
The company is not so keen to sell to the general public so they can test themselves at home, despite the platform's small size and cost (the device – called Miriam – is expected to be free, with each test costing between $100-$150).
"Getting diagnosed with cancer is very different to a pregnancy test," Soto said. "Your doctor needs to give you guidance. Instead, I see our platform as a key resource for doctors."
Not everyone is convinced that this simple form of diagnosis is so close, however. Brad Weinberg, investor and founding partner of heathtech accelerator Blueprint Health, admits he is "a bit skeptical" about the company.
"There are lots of buzzwords and not much substance right now," he told CNBC.
Miroculus hasn't published details of its technology and biochemistry for IP and fundraising reasons, according to Soto. To date, it has been funded solely by the three founders and grants.
Dr Weinberg also highlighted some stumbling blocks in the road for start-ups like Miroculus looking to disrupt diagnosis
"This is a pretty entrenched industry - there's going to be a really long adopter curve," he said. "Plus, the major industry players make billions of dollars with the way the system is right now. They're not going to let it change that quickly."
But he added: "Then again, if there's a way to do tests at the same cost or cheaper, with less pain for stress for patients, there's a big opportunity there."
- By CNBC's Katrina Bishop in Dublin